SCOLR Pharma, Inc. (AMEX: DDD) today announced that its Alliance Partner, Perrigo Company, has launched a fifth sustained-release nutritional product based on SCOLR Pharma’s proprietary CDT(R) oral drug delivery platform. The new product, a “once-daily” CDT-based Calcium private label product, is now being manufactured by Perrigo and shipments have commenced to several national retailers. In addition to an extended-release CDT-based Calcium product, Perrigo markets four other nutritional products based on SCOLR’s proprietary CDT oral drug delivery technology. SCOLR Pharma expects that all five products marketed by Perrigo will be featured at the upcoming National Association of Chain Drug Stores (NACDS) conference to be held June 23-26 in Boston.
SCOLR Pharma’s President and CEO, Daniel Wilds, stated, “We are very pleased that Perrigo has launched and is shipping the once-daily CDT-based Calcium product to a number of its customers. Perrigo continues to be an excellent partner. Together, we have made significant progress in expanding the offering of extended-release nutritional products based on our CDT platform. Both companies are looking forward to the upcoming NACDS conference where our growing portfolio of “once and twice daily” CDT nutritional products will be marketed to some of the largest retailers in the drug and food industry.”
Under the previously reported alliance, Perrigo manufactures, markets and distributes certain of SCOLR’s proprietary formulations or nutritional products in the United States. Perrigo is a global healthcare supplier and the world’s largest manufacturer of OTC pharmaceutical and nutritional products for the store brand and contract manufacturing markets.
About SCOLR Pharma:
Based in Bellevue, Washington, SCOLR Pharma, Inc. is a specialty pharmaceutical company. SCOLR Pharma’s corporate objective is to combine its formulation expertise and its patented CDT platform to develop novel pharmaceutical, over-the-counter (OTC), and nutritional products. Our CDT drug delivery platform is based on multiple issued and pending patents and other intellectual property for the programmed release or enhanced performance of active pharmaceutical ingredients and nutritional products. For more information on SCOLR Pharma, please call 425.373.0171 or visit http://www.scolr.com/.
This press release contains forward-looking statements (statements which are not historical facts) within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve risks and uncertainties, including activities, events or developments that we expect, believe or anticipate will or may occur in the future. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including our ability to successfully develop new formulations and complete research and development, including pre-clinical and clinical studies, our ability to raise additional funds, the continuation of arrangements with our product development partners and customers, competition, government regulation and approvals, and general economic conditions. For example, if our clinical trials are not successful or take longer to complete than we expect, we may not be able to develop and commercialize our products. And we may not obtain regulatory approval for our products, which would materially impair our ability to generate revenue. Additional assumptions, risks and uncertainties are described in detail in our registration statements, reports and other filings with the Securities and Exchange Commission. Such filings are available on our website or at www.sec.gov. You are cautioned that such statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances.
